corporate partnering

Johnson & JohnsonLillyOno

Corporate Partnering is a key component of the Receptos strategy to drive best-in-class and first-in-class therapeutic GPCR candidates into clinical development. Through technology transfer, Receptos will also enable strategic partners to deploy the GPCR crystallography structure determination platform technology within their own drug discovery pipelines.

Receptos entered into partnerships in 2010 with Eli Lilly and the Ortho-McNeil-Janssen division of Johnson & Johnson and with Ono Pharmaceutical Company in 2011.

For further information on the Receptos approach to partnering and current opportunities please contact , Vice President of Corporate Development